Literature DB >> 21082509

Gonadotropin-releasing hormone agonist trigger: the way to eliminate ovarian hyperstimulation syndrome--a 20-year experience.

Shahar Kol1, Joseph Itskovitz-Eldor.   

Abstract

Gonadotropin-releasing hormone agonist (GnRHa) trigger instead of human chorionic gonadotropin in the context of ovarian hyperstimulation syndrome (OHSS) prevention has been used for >20 years. In its first decade it did not gain popularity because it cannot work in GnRHa-based ovarian stimulation protocols. The introduction of GnRH antagonists has revolutionized our ability to eliminate OHSS completely because patients at high risk for OHSS can be triggered with GnRHa. This has been documented in randomized prospective studies, in which none of the patients randomized to the agonist trigger arm developed OHSS. In other words, GnRHa proved to be a potent tool that, truly remarkably, never fails. Although there is some debate concerning the clinical outcome of these cycles, data so far indicate that aggressive luteal support can ensure a good outcome. Moreover, the large number of frozen embryos in these cycles results in excellent per-oocyte retrieval pregnancy rates. In summary, GnRHa ovulatory trigger is the ultimate tool for complete OHSS prevention. GnRH antagonist-based ovarian stimulation protocols should be considered in OHSS high-risk patients so GnRHa trigger can be used if needed. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21082509     DOI: 10.1055/s-0030-1265677

Source DB:  PubMed          Journal:  Semin Reprod Med        ISSN: 1526-4564            Impact factor:   1.303


  5 in total

1.  Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.

Authors:  Jhansi Reddy; Volkan Turan; Giuliano Bedoschi; Fred Moy; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2014-05-23       Impact factor: 3.412

2.  Oocyte cryopreservation in a patient with sickle cell disease prior to hematopoietic stem cell transplantation: first report.

Authors:  Serena Dovey; Lakshmanan Krishnamurti; Joseph Sanfilippo; Sriya Gunawardena; Patricia Mclendon; Mary Campbell; Sandra Alway; Brenda Efymow; Clarisa Gracia
Journal:  J Assist Reprod Genet       Date:  2012-01-05       Impact factor: 3.412

3.  Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome.

Authors:  L Rinaldi; F Lisi; H Selman
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

Review 4.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

5.  Does gonadotropin-releasing hormone agonist cause luteolysis by inducing apoptosis of the human granulosa-luteal cells?

Authors:  Noa Gonen; Robert F Casper; Andrea Jurisicova; Yuval Yung; Moran Friedman-Gohas; Raoul Orvieto; Jigal Haas
Journal:  J Assist Reprod Genet       Date:  2021-05-24       Impact factor: 3.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.